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N-Terminal Pro-B-type Natriuretic Peptide Is Useful to Predict 
Cardiac Complications Following Lung Resection Surgery
Chang  Young  Lee,  M.D.*,  Mi  Kyung  Bae,  M.D.*,  Jin  Gu  Lee,  M.D.*, 
Kwan-Wook  Kim,  M.D.*,  In  Kyu  Park,  M.D.,  Ph.D.*,  Kyung  Young  Chung,  M.D.*
Background:  Cardiovascular complications are major causes of morbidity and mortality following non-cardiac thoracic 
operations. Recent studies have demonstrated that elevation of N-Terminal Pro-B-type natriuretic peptide 
(NT-proBNP) levels can predict cardiac complications following non-cardiac major surgery as well as cardiac 
surgery. However, there is little information on the correlation between lung resection surgery and NT-proBNP 
levels. We evaluated the role of NT-proBNP as a potential marker for the risk stratification of cardiac complications 
following lung resection surgery. Material and Methods: Prospectively collected data of 98 patients, who underwent 
elective lung resection from August 2007 to February 2008, were analyzed. Postoperative adverse cardiac events 
were categorized as myocardial injury, ECG evidence of ischemia or arrhythmia, heart failure, or cardiac death. 
Results: Postoperative cardiac complications were documented in 9 patients (9/98, 9.2%): Atrial fibrillation in 3, 
ECG-evidenced ischemia in 2 and heart failure in 4. Preoperative median NT-proBNP levels was significantly higher 
in patients who developed postoperative cardiac complications than in the rest (200.2 ng/L versus 45.0 ng/L, 
p=0.009). NT-proBNP levels predicted adverse cardiac events with an area under the receiver operating character-
istic curve of 0.76 [95% confidence interval (CI) 0.545∼0.988, p=0.01]. A preoperative NT-proBNP value of 160 
ng/L was found to be the best cut-off value for detecting postoperative cardiac complication with a positive pre-
dictive value of 0.857 and a negative predictive value of 0.978. Other factors related to cardiac complications by 
univariate analysis were a higher American Society of Anesthesiologists grade, a higher NYHA functional class and 
a history of hypertension. In multivariate analysis, however, high preoperative NT-proBNP level (＞160 ng/L) only 
remained significant. Conclusion: An elevated preoperative NT-proBNP level is identified as an independent pre-
dictor of cardiac complications following lung resection surgery. 
Key words: 1. Cardiac
2. Complication
3. Lung surgery
4. Prognosis
INTRODUCTION
Cardiovascular complications are major causes of morbidity 
and mortality following non-cardiac thoracic operations [1]. In 
order to improve risk stratification and predictability of poten-
tial postoperative complications, various tools, such as revised NT-proBNP as a Predictor of Cardiac Complications 
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cardiac  risk  index  (RCRI)  or  American  College  of  Cardiolo-
gy/American Heart Association clinical risk factors, have been 
developed.  These  tools,  however,  cannot  entirely  replace  a 
physician’s  judgment  for  individual  patients,  particularly  be-
cause of the complexity of these diagnostic tools and the lack 
of  evidentiary  support  for  their  usefulness  [2]. 
Therefore,  simple  and  reliable  method  for  identifying 
h i g h - r i s k  p a t i e n t s  i s  n e c e s s a r y .  I t  w o u l d  a l l o w  a  m o r e  t a r -
geted  and  more  cost-effective  application  of  prophylactic 
interventions.  It  would  also  enable  us  to  detect  postoperative 
cardiac  complications  earlier  through  vigilant  surveillance 
over  selected  high-risk  patients. 
Cardiac  natriuretic  peptides  including  brain  natriuretic  pep-
tide  (BNP)  and  N-terminal  proBNP  (NT-proBNP)  have  re-
cently  emerged  as  potentially  useful  biomarkers  in  the  diag-
nosis  and  prognostic  stratification  of  heart  failure  patients  as 
well  as  patients  in  other  clinical  settings  such  as  liver  cir-
rhosis  or  chronic  renal  failure  [3,4].  More  recently,  it  has 
been  reported  that  these  biomarkers  are  elevated  in  patients 
who  experience  perioperative  cardiac  complications  following 
major  cardiac  and  non-cardiac  surgery  [5-7].  However,  there 
is  little  information  on  the  correlation  between  lung  resection 
surgery  and  NT-proBNP  levels. 
We evaluated the role of NT-proBNP as a potential marker 
for  the  risk  stratification  of  cardiac  complications  following 
lung  resection  surgery. 
MATERIAL AND METHODS
1) Study sample
One  hundred  one  consecutive  patients,  who  underwent 
elective  lung  resection  surgery  at  our  institute  from  August 
2007  to  February  2008,  were  enrolled  in  this  prospective 
study.  Among  them,  three  patients  were  excluded  due  to 
newly  developed  arrhythmia  during  anesthesia  or  significant 
hypotension  related  to  perioperative  bleeding  because  the  ob-
jective  of  this  study  was  to  observe  the  net  effect  of  pulmo-
nary  resection  on  the  development  of  cardiac  complications. 
Thus, 98 patients constituted the study cohort. Twenty-six pa-
tients  had  a  history  of  hypertension  and  6  of  them  had  been 
taking  beta-blocker.  Five  patients  out  of  seven  patients  who 
had  a  history  of  coronary  artery  occlusive  disease  had  re-
ceived  a  percutaneous  coronary  artery  intervention  (PCI)  or 
coronary  artery  bypass  graft  (CABG).  All  patients  underwent 
elective lung resection  surgery  and had been  free  from major 
acute  clinical  events  for  at  least  two  months  before  surgery. 
Patients  were  assessed  prior  to  surgery  by  an  attending  anes-
thesiologist  for  American  Society  of  Anesthesiologists  (ASA) 
s c o r e .  T h e  s t u d y  p r o t o c o l  was  approved  by  the  local 
Institutional  Review  Board. 
2) Data collection
Preoperative  data  collection  encompassed  patient  demo-
graphic  data,  medical  and  surgical  histories,  preoperative 
medications,  12-lead  electrocardiography  (ECG),  pulmonary 
function  tests,  and  the  data  on  renal  and  hepatic  function. 
Preoperative blood samples were also obtained to measure se-
rum  NT-proBNP  level.  The  Revised  Cardiac  Risk  Index 
(RCRI)  was  calculated  from  preoperative  variables  [8].  All 
patients  remained  under  continuous  ECG  monitoring  for  at 
least 24 hours following surgery and underwent daily clinical 
cardiologic  evaluations  before  discharge.  All  data  was  col-
lected  prospectively.
3) Postoperative cardiac events
The  occurrence  of  cardiac-related  death  or  cardiac  compli-
cations  requiring  treatment  (myocardial  injury,  ECG  evidence 
of  ischemia  or  arrhythmia,  or  heart  failure)  before  discharge 
was evaluated. Acute postoperative myocardial injury was de-
fined as the evidence of myocardial cell necrosis (Troponin T 
＞0.1  mg/L).  ECG  evidence  of  ischemia  was  defined  as  the 
development  of  T-wave  inversion  of  greater  than  2  mm,  and 
ST  segment  deviation  of  greater  than  2  mm  in  at  least  two 
contiguous  chest  leads  or  greater  than  1  mm  in  at  least  two 
contiguous limb leads. Arrhythmia was defined as a new sus-
tained  abnormal  cardiac  rhythm.  All  ECGs  were  analyzed  by 
a  cardiologist.  Heart  failure  was  defined  as  an  occurrence  of 
symptoms  of  congestive  heart  failure  (orthopnea  or  dyspnea 
on  exertions,  venous  distention,  cardiomegaly,  ankle  edema, 
etc.)  without  the  evidence  of  pneumonia. 
4) Serum NT-proBNP assays
To  measure  the  serum  NT-proBNP  levels,  blood  samples 
were obtained 12 hours before and after the operation. Before Chang Young Lee, et al
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the preoperative blood sample, patients were asked to lie qui-
etly  in  the  supine  position  to  eliminate  any  potential  effects 
of  posture  and  exercise  on  serum  NT-proBNP  levels. 
NT-proBNP  was  assayed  by  a  semiautomated  analyzer 
(Elecsys-1010, Roche Diagnostics, Germany) using an electro-
chemiluminescence  immunoassay  kit  (Elecsys  NT-proBNP 
Test,  Roche  Diagnostics,  Mannheim,  Germany). 
5) Statistical analysis
Categorical  data  are  presented  as  absolute  values  and 
percentage.  Continuous  variables  are  presented  as  the  mean 
and  standard  deviation.  Fisher’s  exact  test  was  used  to  test 
differences  between  two  independent  categorical  data. 
Differences  between  two  independent  groups  of  continuous 
data were evaluated using Mann-Whitney U-test. To establish 
a  NT-proBNP  cut-off  value  with  appropriate  sensitivity  and 
specificity,  receiver  operating  characteristic  (ROC)  curves 
w e r e  p l o t t e d  a n d  t h e  a r e a  u n der  the  curve  was  estimated. 
Linear  logistic  regression  was  used  to  test  the  cardiac  event 
predictability  of  elevated  NT-proBNP  levels  and  other  se-
lected  parameters.  A  p-value  less  than  0.05  was  considered 
significant.  All  statistical  analyses  were  performed  with  the 
Statistical  Package  for  Social  Science  (SPSS  12.0,  Chicago, 
IL,  USA).
RESULTS
There  were  60  male  and  38  female  patients,  and  their 
mean  age  was  61.1±12.0  years.  Twenty  seven  patients 
(23.5%)  suffered  from  postoperative  complications.  Eight  pa-
tients had pulmonary complications such as pneumonia, acute 
lung injury or bronchopleural fistula, and one patient suffered 
from  chylothorax.  Prolonged  air  leakage  (air  leakage  ＞5 
days) occurred in 8 patients. Nine patients (9.2%) experienced 
cardiac  complications  following  lung  resection  surgery.  Atrial 
fibrillation  occurred  in  3  patients,  ischemic  change  requiring 
vasodilator  therapy  in  2  patients,  and  heart  failure  in  3  pa-
tients  including  one  patient  with  simultaneous  pneumonia. 
One  patient  had  simultaneous  atrial  fibrillation  and  heart 
failure. 
All  cardiac  events  occurred  within  a  week  after  the 
operation.  ECG  changes  were  identified  in  9  patients  (5  with 
T-wave  or  ST  segment  abnormalities  and  4  with  new  onset 
atrial  fibrillation).  All  patients  with  atrial  fibrillation  were 
treated  with  antiarrhythmic  agent.  Among  5  patients  with  T 
wave  or  ST  segment  abnormalities,  two  were  treated  with 
vasodilator  immediately  after  the  operation.  All  of  these  five 
patients’  ECGs  recovered  to  their  preoperative  state  within  7 
days.  Acute  myocardial  injury  did  not  occur  in  any  patient. 
Postoperative  heart  failure  requiring  inotropic  agents  oc-
curred  in  4  patients.  All  of  them  suffered  from  oliguria,  leg 
edema  and  dyspnea  without  the  evidence  of  pneumonia  on  a 
chest X-ray. Notably, ejection fractions determined with echo-
cardiography  decreased  over  10%  and  ejection  fractions  were 
below  40%  in  2  patients. 
The  relationship  between  preoperative  and  postoperative 
NT-proBNP  levels  and  postoperative  cardiac  complications  is 
demonstrated  in  Table  1. 
In  patients  with  cardiac  complications,  both  preoperative 
and  postoperative  NT-proBNP  median  values  were  signifi-
cantly  higher  than  in  patients  not  experiencing  cardiac  com-
plications  (Table  1). 
The areas under  the ROC  curve,  which  signifies the  utility 
of  preoperative  and  postoperative  NT-proBNP  in  predicting 
cardiac  complications  following  lung  resection  surgery,  were 
0.76  [95%  confidence  interval  (CI)  0.545∼0.988,  p=0.01] 
and  0.82  (95%  CI  0.626∼1.024,  p=0.001),  respectively  (Fig. 
1).  The  value  of  160  ng/L  was  found  to  be  the  single  best 
cutoff point for preoperative NT-proBNP in predicting the de-
velopment  of  cardiac  complications.  A  preoperative  NT-pro-
BNP value of 160 ng/L carried a positive predictive value of 
0.857  and  a  negative  predictive  value  of  0.978  for  detecting 
postoperative  cardiac  complications. 
The  univariate  predictors  for  postoperative  complications 
included  a  poor  NYHA  functional  class  (≥2),  a  history  of 
hypertension,  a  higher  ASA  score  (≥2 )  a n d  h i g h e r  N T - p r o -
BNP (＞160 ng/L). In the multivariate analysis, only the pre-
operative  NT-proBNP  remained  significant  as  a  predictor  for 
postoperative  cardiac  complications  (Table  2).
DISCUSSION
In this study, preoperative serum NT-proBNP was indicated 
as  an  independent  predictor  for  cardiac  complications  follow-NT-proBNP as a Predictor of Cardiac Complications 
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Table 1. Clinical and demographic characteristics of patients with or without postoperative cardiac complications 
Patient  characteristics
Patients  with  postoperative 
cardiac  complications  (n=9)
Patients  without  postoperative 
cardiac  complications  (n=89)
p-value
Male
Age  median
Smoking  status
  N e v e r
  F o r m e r
    Current
History  of  hypertension
Use  of  beta-blocker
CAD
Prior  CABG  or  PCI
Creatintine
RCRI≥3
NYHA  class≥2
ASA  grade≥2
LVEF,  %  median
FEV1,  %  predicted
Type  of  operation
    Pneumonectomy
    Bilobectomy
  L o b e c t o m y
    Segmentectomy
VATS
Estimated  blood  loss  (mL),  median
NT-pro  BNP  (ng/L) 
    Preoperative,  median
    Postoperative,  median
7  (77.8%)
69  (57∼78)
2  (22.2%)
6  (66.6%)
1  (11.1%)
6  (66.7%)
1  (11.1%)
2  (22.2%)
1  (11.1%)
0.9  (0.6∼1.9)
2  (22.2%)
6  (66.7%)
8  (89%)
60.0  (31.0∼69.0)
81.7  (44.7∼89.8)
2  (22.2%)
2  (22.2%)
4  (44.4%)
1  (11.1%)
3  (33.3%)
150  (0∼900)
200.2  (21.6∼1,722.0)
674.6  (45.2∼1,932.0)
53  (59.6%)
65  (15∼77)
35  (39.3%)
20  (22.5%)
34  (38.2%)
20  (22.5%)
8  (9.0%)
5  (5.6%)
4  (4.5%)
0.8  (0.6∼1.8)
5  (5.6%)
5  (5.6%)
46  (52%)
65.0  (28.0∼73.0)
81.9  (51.4∼96.8)
6  (6.7%)
12  (13.5%)
66  (74.2%)
5  (5.6%)
36  (40.4%)
200  (50∼1,500)
45.0  (10.6∼355.4)
190.2  (40.1∼1,397.0)
0.287
0.012
0.253
0.004
0.448
0.067
0.390
0.226
0.067
0.001
0.039
0.227
0.874
0.108
0.477
0.061
0.515
0.679
0.042
0.009
0.001
CAD=Coronary  artery  disease;  CABG=Coronary  artery  bypass  graft;  PCI=Percutaneous  coronary  intervention;  RCRI=Revised  Cardiac 
Risk;  Index=NYHA,  New  York  heart  association;  ASA=American  society  of  anesthesiologists;  LVEF=Left  ventricular  ejection  frac-
tion;  FEV1=Forced  expiratory  ventilation  in  1  second;  VATS=Video  assisted  thoracoscopic  surgery.
Fig. 1. ROC curve for preoperative NT-proBNP (solid line) and 
postoperative NT-proBNP (dashed line). ROC=Receiver operating 
characteristic.
ing  lung  resection  surgery  by  a  multivariate  analysis.
Cardiac  complications  occur  frequently  after  lung  resection 
surgery. Atrial fibrillation is  the most common cardiovascular 
complications after thoracic surgery, with a reported incidence 
of 8% to 20% after lobectomy and up to 40% after pneumo-
nectomy  [8,9].  These  events  contribute  significantly  to  mor-
bidity,  mortality  and  the  increased  cost  of  medical  care. 
Hence,  a  proactive  approach  for  identifying  patients  with  a 
higher  risk  for  these  complications  is  necessary. 
Various  tools  have  been  developed  to  improve  risk  strat-
ification  and  predictability  for  postoperative  complications. 
The most widely used risk assessment tool for predicting ma-
jor  cardiac  complications  after  non  cardiac  surgery  is  the  re-
vised cardiac risk index (RCRI) [2]. The six independent risk Chang Young Lee, et al
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Table 2. Univariate and multivariate analysis for predictors of adverse cardiac outcome using logistic regression
Patient  characteristics
Odds  ratio  (95%  CI)
univariate
p-value
O d d s  r a t i o  ( 9 5 % C I )
multivariate
p-value
NT-proBNP  ＞160  ng/L
Age  (＞65  years)
Hypertension
Beta-blocker  use
NYHA  class≥2
RCRI≥3
ASA  score≥2
Ejection  fraction
Estimated  blood  loss≥500  mL
2.28  (1.95∼2.66)
1.09  (0.96∼1.24)
1.21  (1.06∼1.37)
1.08  (0.85∼1.38)
1.67  (1.43∼1.94)
1.23  (0.98∼1.54)
1.13  (1.01∼1.27)
0.98  (0.97∼1.01)
1.06  (0.90∼1.25)
＜0.001
0.195
0.004
0.517
＜0.001
0.066
0.033
0.135
0.475
1.88  (1.21∼2.90)
0.98  (0.89∼1.08)
1.12  (0.85∼1.46)
0.94  (0.66∼1.32)
1.21  (0.77∼1.90)
1.18  (0.83∼1.67)
0.87  (0.61∼1.25)
1.00  (0.99∼1.01)
1.11  (0.74∼1.66)
0.008
0.195
0.389
0.690
0.384
0.338
0.427
0.937
0.592
NYHA=New  York  heart  association;  RCRI=Revised  cardiac  risk  index;  ASA=American  society  of  anesthesiologists.
predictors  in  the  index  include  ischemic  heart  disease,  heart 
failure,  cerebrovascular  disease,  chronic  renal  insufficiency 
(serum  creatinine  level＞2  mg/dL),  insulin-dependent  diabe-
tes  mellitus,  and  high-risk  surgery.  Patients  can  be  classified 
as low (zero or one risk factor), intermediate (two factors), or 
high  (three  or  more  factors)  risk  groups  with  corresponding 
postoperative cardiac complication rates of approximately 1%, 
5%,  and  10%,  respectively.  However,  RCRI  may  not  always 
be  precise  in  predicting  postoperative  cardiac  complications. 
In  our  study,  a  high  RCRI  score  (RCRI≥3 )  w a s  n o t  a s s o -
ciated  with  postoperative  cardiac  complications  (Table  2). 
Many  surgeons  utilize  various  preoperative  imaging  studies 
for  cardiac  function  (including  i.e.  echocardiography,  mag-
netic resonance imaging, and radionuclide studies) to evaluate 
left  ventricular  (LV)  function  [10-13].  It  is  generally  agreed 
that depressed LV function is associated with a higher risk of 
postoperative  cardiac  complications,  but  it  remains  debatable 
whether  these  tests  provide  additional  information  to  routine 
clinical evaluation [14]. Halm et al. [10] reported that an LV 
ejection  fraction  of  less  than  40%  was  associated  with  post-
operative  cardiac  complications,  particularly  heart  failure. 
However,  our  study  demonstrated  that  the  LV  ejection  frac-
tion  did  not  correlate  with  the  risk  of  postoperative  cardiac 
complications  after  lung  resection  surgery  (Table  2). 
It  has  been  suggested  that  NT-proBNP  levels  could  be  a 
useful markers of left ventricular dysfunction in both sympto-
matic  and  asymptomatic  patients.  Plasma  levels  of  atriuretic 
peptides  have  been  reported  to  be  elevated  not  only  in  pa-
tients  with  advanced  heart  failure  or  acute  myocardial  in-
farction,  but  also  in  other  clinical  settings  such  as  liver  cir-
rhosis  or  chronic  renal  failure.  Recently,  several  reports  re-
garding the correlation between NT-proBNP and cardiac com-
plications  following  major  cardiac  and  non-cardiac  surgery 
have  been  published.  However,  there  is  little  information  on 
the  correlation  between  lung  resection  surgery  and 
NT-proBNP  levels.  Cardinale  et  al.  [15]  recently  demon-
strated  that  NT-proBNP  is  a  strong  independent  predictor  of 
postoperative  atrial  fibrillation  in  patients  undergoing  thoracic 
surgery for lung cancer. However, other cardiac complications 
were  not  evaluated  in  that  study,  and  the  comparison  of  the 
predictability of adverse cardiac outcomes between NT-proBNP 
and  other  risk  factors  was  not  elucidated.
Our  study  took  into  account  various  cardiac  complications 
(including  atrial  fibrillation),  and  demonstrated  that  preope-
rative  NT-proBNP  levels  were  an  independent  predictor  of 
the  adverse  outcomes  by  a  multivariate  analysis,  after  adjust-
ing  other  risk  factors  such  as  revised  cardiac  risk  index 
which  is  most  widely  used  for  predicting  major  cardiac 
complications.  This  finding  carries  important  clinical  im-
plications,  and  may  enable  us  to  accurately  stratify  patients 
according  to  their  risk  of  adverse  outcomes.  Awareness  of 
preoperative  NT-proBNP  levels  in  patients  who  are  under-
going  lung  resection  surgery  may  help  preventing  the  occur-
rence  of  cardiac  complications  after  surgery.  Assessment  of 
NT-proBNP  levels  may  offer  a  simple  and  cost-effective 
means  of  identifying  high-risk  patients,  and  may  benefit  the 
patients  by  getting  around  invas i v e  a n d  c o s t l y  p r e o p e r a t i v e  
work-up.NT-proBNP as a Predictor of Cardiac Complications 
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There  is  no  consensus  on  the  cut-off  value  for  abnormal 
NT-proBNP concentrations. When using the chemiluminescent 
kit from Roche Diagnostics, the upper 97.5 percentile level is 
identified as 155 ng/L for men and 84 ng/L for women under 
50  years  of  age.  Between  50  and  65  years,  the  upper  limit 
comes  up  to  222  ng/L  for  men  and  194  ng/L  for  women. 
According to the studies in different clinical settings, the sug-
gested  cut-off  values  of  NT-proBNP  ranged  from  lower  than 
100  ng/L to  higher than  1,000  ng/L [16-19]. We suggested  a 
cut-off value of 160 ng/L for NT-proBNP, but this value may 
need  further  evaluation  before  clinical  application. 
As mentioned above, NT-proBNP level increases in various 
clinical conditions such as left ventricular hypertrophy (LVH), 
left  atrial  enlargement  or  compensated  heart  failure.  Lung  re-
section,  which  may  be  a  precipitating  factor  in  patients  with 
increased  NT-proBNP  level,  brings  a  transient,  but  a  sig-
nificant extent of, pressure load to the heart. We assume that 
this  abrupt  hemodynamic  change  may  bring  about  ischemic 
change on ECG in patient with LVH, atrial fibrillation in pa-
tient  with  left  atrial  enlargement,  and  symptomatic  heart  fail-
ure  in  patient  with  compensated  heart  failure. 
In  addition  to  preoperative  measurements,  we  also  checked 
NT-proBNP  levels  12  hours  after  surgery.  Postoperative  NT- 
proBNP  levels  were  also  useful  to  identify  the  high-risk 
patients.  When  both  preoperative  and  postoperative  NT-pro-
BNP levels were integrated, the sensitivity of NT-proBNP in-
creased from 0.667 to 0.778. These findings suggest that both 
preoperative and postoperative elevation of NT-proBNP levels 
can predict cardiac complications for patients undergoing lung 
resection  surgery. 
Our study had several limitations. Firstly, although NT-pro-
BNP  and  other  preoperative  parameters  were  collected  pro-
spectively,  the  occurrence  of  cardiac  complications  was  ana-
lyzed  retrospectively.  Thus,  it  is  possible  that  some  patients 
may  have  had  very  transient  episodes  of  arrhythmia  which 
went unnoticed. Secondly, only a small number of patients in 
a single center was enrolled in  this study. Thirdly, we exam-
ined only one biologic marker. Presumably, further studies on 
other  preoperative  biologic  markers  may  be  necessary  in  pa-
t i e n t s  w i t h  l o w  N T - p r o B N P  l e v e l s  to  improve  sensitivity  and 
positive  predictive  value  of  the  preoperative  assessment  for 
the  delineation  of  the  patients  with  a  higher  risk  of  post-
operative  cardiac  events. 
CONCLUSION
Elevated  preoperative  NT-proBNP  level  is  identified  as  an 
independent  predictor  for  cardiac  complications  following 
lung resection surgery. This correlation may enable us to plan 
adequate treatments in advance, and to detect cardiac compli-
cations  as  early  as  possible  through  the  monitoring  of  post-
operative  NT-proBNP  levels  in  selected  high-risk  patients. 
Further  studies  are  necessary  to  support  our  observation,  and 
to clarify the relationship between NT–proBNP levels and ex-
isting  methods  of  risk  stratification.
REFERENCES
1 . K a r a m i c h a l i s  J M ,  P u t n a m  J B  J r ,  L a m b r i g h t  E S .  Cardiovas-
cular  complications  after  lung  surgery.  Thorac  Surg  Clin 
2006;16:253-60.
2. Cohn  SL.  Preoperative  cardiac  evaluation  of  lung  resection 
candidates.  Thorac  Surg  Clin  2008;18:45-59.
3. Clerico  A,  Emdin  M.  Diagnostic  accuracy  and  prognostic 
relevance of the measurement of cardiac natriuretic peptides: 
a  review.  Clin  Chem  2004;50:33-50.
4. Phua  J,  Lim  TK,  Lee  KH.  B-type  natriuretic  peptide:  issues 
for  intensivist  and  pulmonologist.  Crit  Care  Med  2005;33: 
2094-103.
5. Yeh  HM,  Lau  HP,  Lin  JM,  Sun  WZ,  Wang  MJ,  Lai  LP. 
Preoperative plasma N-terminal pro-brain natriuretic peptide 
as  a  marker  of  cardiac  risk  in  patients  undergoing  elective 
non-cardiac  surgery.  Br  J  Surg  2005;92:1041-5.
6. Cuthbertson  BH,  Amiri  AR,  Croal  BL,  et  al.  Utility  of 
B-type natriuretic peptide in predicting perioperative cardiac 
events in patients undergoing major non-cardiac surgery. B r  
J  Anaesth  2007;99:170-6.
7. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type 
natriuretic  peptide  levels  predict  postoperative  atrial  fi-
brillation in patients undergoing cardiac surgery. Circulation 
2004;110:124-7.
8. Roselli  EE,  Murthy  SC,  Rice  TW,  et  al.  Atrial  fibrillation 
complicating  lung  cancer  resection.  J  Thorac  Cardiovasc 
Surg  2005;130:438-44.
9. Asamura  H,  Naruke  T,  Tsuchiya  R,  Goya  T,  Kondo  H, 
Suemasu  K.  What  are  the  risk  factors  for  arrhythmias  after 
thoracic  operations?  A  retrospective  multivariate  analysis  of 
267  consecutive  thoracic  operations.  J  Thorac  Cardiovasc 
Surg  1993;106:1104-10.
10. Halm EA, Browner WS, Tubau JF, Tateo IM, Mangano DT. Chang Young Lee, et al
− 50  −
Echocardiography for assessing cardiac risk in patients hav-
ing  noncardiac  surgery.  Study  of  Perioperative  Ischemia 
Research  Group.  Ann  Intern  Med  1996;125:433-41.
11. Pedersen T, Kelbaek H, Munck O. Cardiopulmonary compli-
cations  in  high-risk  surgical  patients:  the  value  of  pre-
operative  radionuclide  cardiography.  Acta  Anaesthesiol 
Scand  1990;34:183-9.
1 2 . L e p p o  J ,  P l a j a  J ,  G i o n e t  M ,  T u m o l o  J ,  P a r a s k o s  J A ,  C u t l e r  
BS.  Noninvasive  evaluation  of  cardiac  risk  before  elective 
vascular  surgery.  J  Am  Coll  Cardiol  1987;9:269-76.
13. Kontos  MC,  Brath  LK,  Akosah  KO,  Mohanty  PK.  Cardiac 
complications  in  noncardiac  surgery:  relative  value  of  rest-
ing  two-dimensional  echocardiography  and  dipyridamole 
thallium  imaging.  Am  Heart  J  1996;132:559-66.
14. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for 
perioperative  cardiovascular  evaluation  for  noncardiac  sur-
gery.  Report  of  the  American  College  of  Cardiology/Ameri-
can  Heart  Association  Task  Force  on  Practice  Guidelines 
(Committee  on  Perioperative  Cardiovascular  Evaluation  for 
Noncardiac  Surgery).  J  Am  Coll  Cardiol  1996;27:910-48.
15. Cardinale  D,  Colombo  A,  Sandri  MT,  et  al.  Increased  peri-
operative  N-terminal  pro-B-type  natriuretic  peptide  levels 
predict  atrial  fibrillation  after  thoracic  surgery  for  lung 
cancer.  Circulation  2007;115:1339-44.
16. Hunt  PJ,  Richards  AM,  Nicholls  MG,  Yandle  TG,  Doughty 
RN,  Espiner  EA.  Immunoreactive  amino-terminal  pro-brain 
natriuretic  peptide  (NT-PROBNP):  a  new  marker  of  cardiac 
impairment.  Clin  Endocrinol  (Oxf)  1997;47:287-96.
1 7 .T a l w a r  S ,  S q u i r e  I B ,  D a v i e s  J E ,  B a r n e t t  D B ,  N g  L L .  
Plasma  N-terminal  pro-brain  natriuretic  peptide  and  the 
ECG in the assessment of left-ventricular systolic dysfunction 
in  a  high  risk  population.  Eur  Heart  J  1999;20:1736-44.
18. Richards  AM,  Nicholls  MG,  Yandle  TG,  et  al.  Plasma 
N-terminal pro-brain natriuretic peptide and adrenomedullin: 
new  neurohormonal  predictors  of  left  ventricular  function 
and  prognosis  after  myocardial  infarction.  Circulation  1998; 
97:1921-9.
19. Jernberg  T,  Stridsberg  M,  Venge  P,  Lindahl  B.  N-terminal 
pro  brain  natriuretic  peptide  on  admission  for  early  risk 
stratification  of  patients  with  chest  pain  and  no  ST-segment 
elevation.  J  Am  Coll  Cardiol  2002;40:437-45.